DiagnaMed Holdings Corp. (TSE:DMED) has released an update.
DiagnaMed Holdings Corp. has filed a provisional patent application in the U.S. for new methods of producing molecular hydrogen aimed at treating neurological and mental health disorders. The company plans to partner with research institutions and life sciences companies to manufacture and commercialize this product, expected to be available by December 2024. This development could represent a significant advancement in the treatment of conditions like dementia, Parkinson’s disease, depression, and anxiety.
For further insights into TSE:DMED stock, check out TipRanks’ Stock Analysis page.
